![Kelly Norsworthy: Submit your Pragmatic Trials ideas to FDA Oncology](https://oncodaily.com/pub/uploads/2024/05/9_48wgHO_400x400.png)
Kelly Norsworthy: Submit your Pragmatic Trials ideas to FDA Oncology
Kelly Norsworthy, Deputy Division Director, Division of Hematologic Malignancies 1 at Johns Hopkins University, shared a post on X:
“Last chance to submit your Pragmatic Trials ideas to FDA Oncology! Or simply log in to the crowdsourcing platform to see ideas others have posed – comment, like, and pick your favorites!”
Amer Zeidan retweeted this post, adding the following:
“An outstanding initiative by our colleagues in the FDA Oncology, Kelly Norsworthy. Take a look and provide comments”
Source: Kelly Norsworthy/X and Amer Zeidan/X
Amer Zeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid Malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division and chairs the Protocol Review Committee (PRC) at Yale Cancer Center.
Dr. Zeidan is a well-known leukemia researcher with a special focus on targeted therapies and immunotherapy for myeloid malignancies, and a social media influencer in the field of blood cancer.